Be Ready for the New Oral GLP-1 Agonist Orforglipron

May 2026

You’ll get questions about orforglipron (Foundayo), the second ORAL GLP-1 receptor agonist approved for adults with overweight or obesity.

It’s another DAILY option...like oral semaglutide (Wegovy).

But orforglipron can be taken with or without food. Oral semaglutide must be taken with a max of 4 oz of water at least 30 minutes before the first food, other beverage, or oral meds of the day.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

GLP-1 Agonists Be Ready for the New Oral GLP-1 Agonist Orforglipron
Rumor vs Truth Use Evidence to Clear up Questions About Gabapentin
Dyslipidemia New Cholesterol Guidelines: Screening, Risk, and Targets
Pain Brush Up on Non-Opioid Pain Medications
Women's Health Help With Estrogen Patch Shortages
Seizures Guide Safety and Monitoring of Antiseizure Meds
Contraceptives Etonogestrel Implant (Nexplanon) Updates
NatMed Spotlight Sort Out Claims About Lion’s Mane Mushroom

Be Ready for the New Oral GLP-1 Agonist Orforglipron

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents